This work aimed to evaluate the association between U‐p53AZ with established cerebrospinal fluid (CSF) and neuroimaging measures, and to determine its diagnostic performance in distinguishing cognitively normal individuals from those with mild cognitive impairment (MCI).
Abstract
Early diagnosis of Alzheimer's disease (AD) is critical for improving patient outcomes. The laboratory‐developed blood test of AlzoSure measures the unfolded conformational variant of p53 (U‐p53AZ) in plasma and has shown promise as a screening tool for AD risk. We aimed to evaluate the association between U‐p53AZ with established cerebrospinal fluid (CSF) and neuroimaging measures, and to determine its diagnostic performance in distinguishing cognitively normal (CN) individuals from those with mild cognitive impairment (MCI).
Plasma tau biomarkers, particularly plasma p-tau217, have consistently shown excellent diagnostic performance across the AD continuum, recently culminating in regulatory approval of plasma p-tau217-based assays in both the USA and Europe.
Lucilla Parnetti, L. Gaetani· EBioMedicine· 0 citations
Digital cognitive assessments that target Alzheimer’s-disease-vulnerable systems can detect earlier functional change and strengthen plasma-biomarker prognosis.
C. Vanderlip, Craig E. L. Stark· Nature Aging· 0 citations
In a peripheral real-world memory clinic setting the BBMs demonstrated high concordance with clinically diagnosed dementia due to AD, suggesting utility of BBMs in peripheral memory clinic practice, in patients with suspected dementia.
Marleen Kloppenburg-Lagendijk, Claire Van Nyendaal, I. Verberk et al.· Journal of Alzheimer's Disea...· 0 citations
The proposed 3D CNN accurately distinguished DAT from cognitively normal controls using amyloid PET imaging and showed promising performance across the AD continuum, supporting the potential of deep learning for early AD detection and clinical decision support.
Mitchell Edema, K. Popuri, Hyunwoo Lee et al.· Journal of Alzheimer's Disea...· 0 citations
The authors critically appraise the current evidence supporting plasma phosphorylated tau at threonine 217 (p-tau217) as the leading BBM for AD, and highlight current limitations, unresolved challenges, and future perspectives for the integration of plasma biomarkers into routine clinical practice.
L. Gaetani, Giovanna Nardi, Lucilla Parnetti· Expert Review of Neurotherap...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
